EZH-302: SYMPHONY-1: A Phase 1B/3 Double-blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat/EPZ-6438 or Placebo in Combination with Lenalidomide plus Rituximab (R^2) in Subjects with Relapsed/Refractory Follicular Lymphoma
- Title
- SYMPHONY-1: A Phase 1B/3 Double-blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat/EPZ-6438 or Placebo in Combination with Lenalidomide plus Rituximab (R^2) in Subjects with Relapsed/Refractory Follicular Lymphoma
- Principal Investigator
- Bhatnagar, Bhavana
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Lymphoma
- Participating Institutions
- Wheeling Hospital
- Contacts
- Maher Kali, MD
- Clinical Research Specialist-WVUCI
- Phone: +1 304-243-7045
- Email: maher.kali@wvumedicine.org